Skip to content

Guardian Pharmacy Services GRDN Additional Paid-In Capital

Additional Paid-In Capital at other companies

BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$1.96B+4.5%
Omnicell logo
OmnicellOMCL
$1.24B+4.5%
PACS Group logo
PACS GroupPACS
$646.74M+7.2%
GHC
Graham HoldingsGHC
$346.94M-5.7%
Elevance Health logo
Elevance HealthELV
$8.85B-0.2%

Other financials

Income statement

See full
Revenue$336.6M+2.2%
Gross profit$76.3M+18.6%
Operating income$17.7M+35.9%
Net income$13.3M+40.7%
EPS (diluted)$0.21+40.0%

Balance sheet

See full
Cash & equivalents$64.9M+364%
Total debt$36.9M+29.6%
Total equity$232.4M+42.4%
Total assets$426.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M-65.5%
CapEx$495.0K-78.0%
Free cash flow$34.1M+69.8%

Valuation

See full
Market cap$2.48B+80.1%
Enterprise value$2.45B+76.1%
P/E46.8×
P/S1.7×+0.6×

Profitability

See full
Gross margin20.9%+1.1pp
Operating margin5.3%
Net margin3.6%+2.1pp

Returns & leverage

See full
Return on equity26.8%
Debt / equity0.2×0.0×
Current ratio1.5×+0.3×

Where this comes from

Reported directly by Guardian Pharmacy Services in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Guardian Pharmacy Services’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Guardian Pharmacy Services's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Guardian Pharmacy Services's additional paid-in capital?
Guardian Pharmacy Services (GRDN) reported additional paid-in capital of $141.19M in Q1 2026.
How has Guardian Pharmacy Services's additional paid-in capital changed year-over-year?
Guardian Pharmacy Services's additional paid-in capital increased by 9.1% year-over-year, from $129.45M to $141.19M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.